Cynthia M. Butitta Sells 10,000 Shares of Kite Pharma Inc. (KITE) Stock

Kite Pharma Inc. (NASDAQ:KITE) COO Cynthia M. Butitta sold 10,000 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $50.40, for a total value of $504,000.00. Following the completion of the sale, the chief operating officer now owns 105,477 shares in the company, valued at approximately $5,316,040.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Kite Pharma Inc. (NASDAQ:KITE) opened at 50.93 on Thursday. Kite Pharma Inc. has a 12 month low of $38.41 and a 12 month high of $86.79. The stock’s market capitalization is $2.54 billion. The company’s 50 day moving average price is $48.48 and its 200-day moving average price is $52.52.

Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($1.49) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.14. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. The firm had revenue of $7.34 million for the quarter, compared to analysts’ expectations of $4.94 million. During the same period in the previous year, the firm posted ($0.38) EPS. The business’s revenue for the quarter was up 43.1% compared to the same quarter last year. Equities analysts predict that Kite Pharma Inc. will post ($5.56) earnings per share for the current year.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/12/01/cynthia-m-butitta-sells-10000-shares-of-kite-pharma-inc-kite-stock.html.

A number of equities research analysts have commented on the company. RBC Capital Markets reiterated a “buy” rating on shares of Kite Pharma in a research report on Thursday, November 24th. Jefferies Group restated a “buy” rating on shares of Kite Pharma in a research report on Wednesday, November 23rd. Vetr lowered Kite Pharma from a “hold” rating to a “sell” rating and set a $57.97 target price on the stock. in a research report on Monday, August 15th. Barclays PLC upped their target price on Kite Pharma from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 27th. Finally, Canaccord Genuity set a $75.00 target price on Kite Pharma and gave the company a “buy” rating in a research report on Wednesday, October 19th. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $71.57.

Several hedge funds have recently modified their holdings of KITE. Bainco International Investors boosted its stake in shares of Kite Pharma by 2,722.8% in the third quarter. Bainco International Investors now owns 671,540 shares of the biopharmaceutical company’s stock worth $37,512,000 after buying an additional 647,750 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Kite Pharma by 117.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 521,568 shares of the biopharmaceutical company’s stock valued at $29,135,000 after buying an additional 281,826 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in Kite Pharma by 69.3% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 8,065 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 3,300 shares during the period. Credit Suisse AG boosted its position in Kite Pharma by 38.2% in the third quarter. Credit Suisse AG now owns 94,770 shares of the biopharmaceutical company’s stock valued at $5,295,000 after buying an additional 26,197 shares during the period. Finally, Boyer & Corporon Wealth Management LLC boosted its position in Kite Pharma by 1.8% in the third quarter. Boyer & Corporon Wealth Management LLC now owns 10,203 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 178 shares during the period. 77.79% of the stock is currently owned by hedge funds and other institutional investors.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.


 Comment on this Post

 

Cynthia M. Butitta Sells 10,000 Shares of Kite Pharma Inc. (KITE) Stock

Kite Pharma Inc. (NASDAQ:KITE) COO Cynthia M. Butitta sold 10,000 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $50.40, for a total value of $504,000.00. Following the completion of the sale, the chief operating officer now owns 105,477 shares in the company, valued at approximately $5,316,040.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Kite Pharma Inc. (NASDAQ:KITE) opened at 50.93 on Thursday. Kite Pharma Inc. has a 12 month low of $38.41 and a 12 month high of $86.79. The stock’s market capitalization is $2.54 billion. The company’s 50 day moving average price is $48.48 and its 200-day moving average price is $52.52.

Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($1.49) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.14. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. The firm had revenue of $7.34 million for the quarter, compared to analysts’ expectations of $4.94 million. During the same period in the previous year, the firm posted ($0.38) EPS. The business’s revenue for the quarter was up 43.1% compared to the same quarter last year. Equities analysts predict that Kite Pharma Inc. will post ($5.56) earnings per share for the current year.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/12/01/cynthia-m-butitta-sells-10000-shares-of-kite-pharma-inc-kite-stock.html.

A number of equities research analysts have commented on the company. RBC Capital Markets reiterated a “buy” rating on shares of Kite Pharma in a research report on Thursday, November 24th. Jefferies Group restated a “buy” rating on shares of Kite Pharma in a research report on Wednesday, November 23rd. Vetr lowered Kite Pharma from a “hold” rating to a “sell” rating and set a $57.97 target price on the stock. in a research report on Monday, August 15th. Barclays PLC upped their target price on Kite Pharma from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 27th. Finally, Canaccord Genuity set a $75.00 target price on Kite Pharma and gave the company a “buy” rating in a research report on Wednesday, October 19th. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $71.57.

Several hedge funds have recently modified their holdings of KITE. Bainco International Investors boosted its stake in shares of Kite Pharma by 2,722.8% in the third quarter. Bainco International Investors now owns 671,540 shares of the biopharmaceutical company’s stock worth $37,512,000 after buying an additional 647,750 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Kite Pharma by 117.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 521,568 shares of the biopharmaceutical company’s stock valued at $29,135,000 after buying an additional 281,826 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in Kite Pharma by 69.3% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 8,065 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 3,300 shares during the period. Credit Suisse AG boosted its position in Kite Pharma by 38.2% in the third quarter. Credit Suisse AG now owns 94,770 shares of the biopharmaceutical company’s stock valued at $5,295,000 after buying an additional 26,197 shares during the period. Finally, Boyer & Corporon Wealth Management LLC boosted its position in Kite Pharma by 1.8% in the third quarter. Boyer & Corporon Wealth Management LLC now owns 10,203 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 178 shares during the period. 77.79% of the stock is currently owned by hedge funds and other institutional investors.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.


 Comment on this Post

 
Facebook
Twitter
LinkedIn
StockTwits
Google Plus
Reddit